Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Natural and engineered extracellular vesicles in vascular diseases: a focus on therapeutic effects, challenges and prospective

Ahmadi M., Abbasi R., Keyhanmanesh R., Mesgin RM., Abdyazdani N., Shoaran M.

Narrative Review on Face & Skin, Systemic / IV, published in Eur J Med Res (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Eur J Med Res (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40597441
PMCID
PMC12210656
DOI
10.1186/s40001-025-02822-x

Abstract (original English)

Vascular diseases (VD), such as cardiovascular diseases, cerebrovascular diseases, and diabetic diseases, originate from numerous pathophysiological changes and remain a serious public health concern. Extracellular vesicles (EVs) produced by cells contribute to regulating VD either dangerously or beneficially. The term EVs refers to the heterogeneous population of vesicles, such as exosomes and microvesicles that participate in cell communication during VD. EVs from different cells, especially those of stem cells, show great promise in the improvement of various VD. They can repair cellular damage, enhance and recover cell function, multiply cells, and prevent cell death and inflammation in specific tissues/cells. EVs have the potential to enhance conditions like cardiovascular disease, cerebrovascular disorders, and complications related to diabetes. Furthermore, an increasing amount of evidence indicates that EVs can be altered/loaded to create a drug delivery system for transporting therapeutic agents to cells, improving different VD. Different methods are used to engineer EVs to improve the efficacy of natural EVs. Despite the potential clinical application of EVs, this field facese many problems that need to be addressed. These limitations and challenges have unmasked the unexpected complexity of EVs regulatory mechanisms, and inspiring advances have been achieved.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansVascular DiseasesDrug Delivery SystemsCell CommunicationExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research